Why the study?
Does dabigatran reduce ischemic stroke, intracranial hemorrhage, and death compared to warfarin in patients with atrial fibrillation and a risk of stroke?
Does dabigatran reduce ischemic stroke, intracranial hemorrhage, and death compared to warfarin in patients with atrial fibrillation and a risk of stroke?
Dabigatran was associated with lower rates of ischemic stroke and all-cause mortality compared to warfarin in patients with atrial fibrillation.
Answers are grounded in this paper and cite their sources.
Dabigatran was associated with lower ischemic stroke and mortality than warfarin in AF; hypothesis-generating and should not yet change practice.
Safety issues have been raised about dabigatran. We aimed to investigate the occurrence of safety outcomes in patients who had atrial fibrillation and a risk of stroke. We analyzed 439 patients prescribed dabigatran (n = 220) or warfarin (n = 219). Ischemic stroke occurred in 15 (6.8%) patients in the warfarin group versus 5 (5.2%) patients in the 110-mg group versus 1 (0.8%) patient in the 150-mg dabigatran group (P = .015). Intracranial hemorrhage occurred in 6 (2.7%) patients in the warfarin group versus 3 (2.4%) patients in the 150-mg dabigatran group (P = .104). Death from any cause occurred in 10 (4.6%) patients in the warfarin group versus 1 (1.0%) patient in the 110-mg dabigatran group (P = .005). Dabigatran was associated with less ischemic stroke and death from any cause than warfarin. Dabigatran may be a better option for stroke prophylaxis, where recommended monitoring with warfarin is suboptimal.
No takes yet. Share an insight, caveat, or question.
Aslan et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: